AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 301 min read$VNDA

Vanda posts late-stage trial win for HETLIOZ in DSWPD (VNDA)

Vanda Pharmaceuticals (VNDA) reported positive late-stage trial results for Hetlioz in treating adults with delayed sleep-wake phase disorder, aiming for FDA label expansion.

Original reporting
seekingalpha.com
Published Sep 30, 2026, 10:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VNDA
Bullish
high confidence
Mentioned
$VNDA
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VNDABullishMed
01

Why it matters

The trial success could expand the drug's label, increasing revenue potential and attracting partnership interest.

02

Market read

First‑report of pivotal trial data for a listed biotech, likely to move VNDA and influence related stocks.

03

What to watch

Potential competition from other melatonin‑receptor agents could temper long‑term growth.

Relevance 8/10Novelty 8/10Timing: today

Background

Vanda Pharmaceuticals is a U.S. biotech focused on central nervous system disorders. Hetlioz (tasimelteon) is already FDA‑approved for non‑24‑hour sleep‑wake disorder.

Company-level read

Ticker impact

$VNDABullishHigh confidence
Context

Vanda Pharmaceuticals reported positive late‑stage trial data for Hetlioz in adults with delayed sleep‑wake phase disorder, a new label expansion opportunity.

Expected impact

upward pressure as the market prices in the label expansion potential

Evidence & confidence

First‑report of pivotal trial data for a listed biotech typically triggers a price rally.

Market effects

Sector

Strengthens the sleep‑disorder therapeutic segment and may boost peer biotech valuations.

Regional

U.S. biotech market sees fresh catalyst; limited immediate effect on other regions.

Global

Adds to global pipeline confidence for sleep‑disorder treatments.

Counterpoint

What could challenge this read

If the FDA requires additional data or the market has already priced in the win, upside may be limited.

Key entities

  • company
    Vanda Pharmaceuticals

    U.S. biotech developing sleep‑disorder therapies.

  • product
    Hetlioz (tasimelteon)

    FDA‑approved sleep‑disorder medication now showing efficacy in DSWPD.

Read at source← All news

Related articles

OCT 14
$VNDAHighAI 8/10

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.

investing.com2 min
OCT 14
$VNDAMedAI 8/10

Vanda’s phase III trial for social anxiety drug fails

Vanda Pharmaceuticals (VNDA) reported that its phase III trial for VQW-765, a drug for social anxiety, failed to meet primary and secondary endpoints. The study showed no significant difference in distress levels between the drug and placebo. The company has paused the program pending further analysis. The drug was safe and well-tolerated, according to the company.

investing.com2 min
OCT 14
$VNDAMedAI 8/10

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals (VNDA) reported that its Phase III study of VQW-765 for social anxiety disorder did not meet the primary endpoint, failing to show a significant difference from placebo. The study evaluated 546 adults and did not confirm earlier Phase II results. The company plans to analyze the full dataset before deciding next steps. VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor partial agonist.

prnewswire.com2 min
OCT 5
$VNDAMedAI 8/10

Wainwright reiterates Buy on Vanda stock after sleep disorder trial

H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.

investing.com2 min
SEP 30
$VNDAHighAI 8/10

Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up

Vanda Pharmaceuticals (VNDA) reported positive Phase 3 results for HETLIOZ in treating Delayed Sleep-Wake Phase Disorder, meeting primary endpoints. HETLIOZ shifted sleep onset 37.1 minutes earlier vs. placebo. The company plans to discuss results with the FDA and submit an sNDA. HETLIOZ sales declined 66% YoY in Q2 2026, partly due to shipment timing. VNDA stock is up 10.14% in overnight trading.

rttnews.com2 min
SEP 29
$VNDAHighAI 9/10

Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

investing.com2 min